Non-Hodgkin Lymphoma Clinical Trials in Baltimore, Maryland

7 studies are recruiting for non-hodgkin lymphoma in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

   This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Maryland, Baltimore, Maryland

   Locations

   15 in total

   Run by

   Imugene Limited

   See if you can join NCT03666000 on ClinicalTrials.gov

2. Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

   This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

   Locations

   11 in total

   Run by

   Miltenyi Biomedicine GmbH

   See if you can join NCT06116110 on ClinicalTrials.gov

3. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

   This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

   Stage

   Not phased

   Ages

   Any age

   Site

   Johns Hopkins, Baltimore, Maryland

   Locations

   142 in total

   Run by

   Center for International Blood and Marrow Transplant Research

   See if you can join NCT01351545 on ClinicalTrials.gov

4. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

   This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland

   Locations

   467 in total

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT06418204 on ClinicalTrials.gov

5. AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

   This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland

   Locations

   13 in total

   Run by

   Carna Biosciences, Inc.

   See if you can join NCT05602363 on ClinicalTrials.gov

6. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Baltimore, Maryland

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov

7. Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

   This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patie…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06398457 on ClinicalTrials.gov